

**Onchocerciasis: 1998 Mectizan treatment figures for
Global 2000 River Blindness Program (GRBP)-assisted areas in
Nigeria, Cameroon, Uganda, and collaborative programs in Latin America and Sudan**

Country/Tx														TOTAL	% ATO	% ALL
Category		Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec			GRBP TX
NIGERIA	*ATO(earp)=	4030000		ATO(arv)=	10524		ATO(hrv)=	6979								
TX(earp)		11962	314252	606072	438164	681079	1217547	332801	179640	55482	35802	38696	979	3912476	97%	69%
TX(arv)		30	839	985	920	1730	2459	962	614	306	69	553	4	9471	90%	66%
TX(hrv)		30	726	892	877	1551	1957	501	279	94	62	119	4	7092	102%	83%
UGANDA	*ATO(earp)=	845000		ATO(arv)=	1804		ATO(hrv)*=	1804								
TX(earp)				9190	219523	145323	30741	19500	157,209	144702	76841	15725	8923	827677	98%	15%
TX(arv)				294	293	294	158	158	158	450				1805	100%	13%
TX(hrv)														0	0%	0%
CAMEROON	ATO(earp)=	599395		ATO(arv)=	2053		ATO(hrv)=	1613								
TX(earp)		35788	21063	27591	40346	38026	48,584	24710	22561	25245	2467	45929	74971	407281	68%	7%
TX(arv)		125	86	156	172	150	163	102	40	65	10	22	213	1304	64%	9%
TX(hrv)		91	72	154	170	159	130	102	39	40	7	19	168	1151	71%	14%
OEPA*	ATO(earp)=	358875		ATO(arv)=	1799		ATO(hrv)=	252								
TX(earp)				109418			78550					42110	40544	270622	75%	5%
TX(arv)				903			187					212	387	1689	94%	12%
TX(hrv)				118			70					11	75	274	109%	3%
SUDAN	ATO(earp)=	752620		ATO(arv)=			ATO(hrv)=									
TX(earp)		3686	2266	1500			104932		9945	30224	19437	16390	3105	208711	28%	4%
TX(arv)																
TX(hrv)																
Cumulative totals	ATO(earp)=	5833270		ATO(arv)=	16180		ATO(hrv)=	10648								
TX(earp)		51436	337581	753771	698033	864428	1480354	377011	369355	255653	134547	158850	128522	5626767	96%	100%
TX(arv)		155	925	2338	1385	2174	2967	1222	812	821	79	787	604	14269	88%	100%
TX(hrv)		121	798	1164	1047	1710	2157	603	318	134	69	149	247	8517	80%	100%

ATO: Annual Treatment Objective TX: Number Treated earp: Eligible At Risk Population arv: At Risk Villages hrv: High Risk Villages (nodule prevalence >39% or mf prevalence >59%)

*OEPA figures reported quarterly: hrv villages reflect prevalence at time of initiation of Mectizan therapy; Mexico uses >49% mf prevalence as hrv definition
Number of hrv villages in Uganda is unknown

